Biologics
Chime Biologics and MedPacto Form Strategic Partnership to Accelerate Global Biologics Development and Manufacturing
Chime Biologics
PR-10-24-NI-66Oct 29, 2024
Clinical Trials
TREMFYA is the first and only IL-23 inhibitor to demonstrate robust results with regimen in both induction and maintenance
Johnson & Johnson
PR-10-24-NI-64Oct 28, 2024
Advanced Therapies
A New Vision for Progressing Advanced Therapies
Nathaniel Youndt
ReciBioPharm
PAO-10-24-CL-13Oct 25, 2024
Biopharma
Life Sciences and Cryoport Form Partnership to Elevate Standards for Frozen Egg, Embryo, etc Offsite Storage and Biologistics
Cryoport
PR-10-24-NI-52Oct 21, 2024
Clinical Development
MOBILion Systems Unveils Novel High Resolution Mass Spectrometry Functionality for Proteomics Workflows
MOBILion Systems, Inc.
PR-10-24-NI-51Oct 21, 2024
Financing
mRNA Synthesis & Manufacturing Market to Hit USD 738.3 Million by 2029 with 3.4% CAGR | MarketsandMarkets™
MarketsandMarkets™
PR-10-24-NI-50Oct 17, 2024
Clinical Trials
Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
Novavax
PR-10-24-NI-48Oct 17, 2024
Clinical Trials
Harbour BioMed Announces the Phase I Study Results in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors
Harbour BioMed
PR-10-24-NI-39Oct 11, 2024
Clinical Trials
StemCyte's HPC Cord Blood Receives RMAT Designation for Long COVID-19 Treatment
StemCyte
PR-09-24-NI-28Oct 07, 2024
Clinical Trials
Soligenix Announces Partnership with Sterling Pharma Solutions
Soligenix, Inc.
PR-09-24-NI-32Oct 07, 2024
Cell Therapy
Cryoport launches its IntegriCell™ cryopreservation solution with opening of new facility at its Houston Campus
Cryoport
PR-10-24-NI-35Oct 07, 2024
FDA
Thryv Therapeutics Granted FDA Orphan Drug Designation for LQT-1213 in Long QT Syndrome Treatment
Thryv Therapeutics Inc
PR-09-24-NI-27Oct 03, 2024
FDA
PTC Therapeutics Announces FDA Acceptance for Filing of NDA for the Treatment of Pediatric and Adult Phenylketonuria Patients
PTC Therapeutics, Inc.
PR-09-24-NI-26Oct 03, 2024
Cell Therapy
Agile Cell Supply and Processing to Accelerate Development of the Medicines of the Future
Justin Irizarry, CFA
OrganaBio
PAO-09-24-CL-11Sep 30, 2024
Clinical Trail
TALVEY and DARZALEX FASPRO shows deep and durable responses in patients with relapsed or refractory multiple myeloma
Johnson & Johnson
PR-09-24-NI-21Sep 27, 2024
Clinical Trails
TALVEY and TECVAYLI suggests high response rates in triple-class refractory patients with relapsed or refractory multiple myeloma
Johnson & Johnson
PR-09-24-NI-20Sep 27, 2024
Clinical Trials
AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
AbbVie
PR-09-24-NI-17Sep 26, 2024
CDMO
Wheeler Bio Licenses ATUM’s miFuc Technology to Expand Their Portable CMC Platform Capabilities
Wheeler Bio
PR-09-24-NI-14Sep 24, 2024
Clinical Trail
Immusoft to Announce Positive Phase 1 Data for First Engineered B Cell Therapy in a Clinical Trial
Immusoft
PR-09-24-NI-11Sep 23, 2024
.png?width=3840&quality=75&resize=contain)
CDMO
Serán Bioscience Announces $200 Million Strategic Growth Transaction and Plans for New Commercial Facility
Serán Bioscience
PR-09-24-NI-07Sep 17, 2024